Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD
See if you are eligible Potency Test This test is performed every 3 to 6 months
Reduction in Risk Across Fourteen Obesity-Related Cancers A large observational study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, involving more than 170,000 patients with diabetes and obesity, found that GLP-1 receptor agonists were associated with a modest but statistically meaningful reduction in the incidence of 14 obesity-related cancers , with colorectal cancer demonstrating particularly favourable outcomes when compared to patients receiving DPP-4 inhibitors
Sensitive patients still need caution: Generally low risk with limited systemic effect, but can potentially can cause flares in individuals with MCAS, histamine intolerance, CIRS, or high reactivity
Myhr, E.G
